15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Keros Therapeutics Inc, 3 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $16.00 to $27.00, a moderate spread. The average target of $20.60 sits 84% above the current $11.18. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.78 next quarter toward $-6.62 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Moderate Buy
Strong Buy00%
Buy360%
Hold240%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Keros Therapeutics Inc.
As of Sep, 3 of 5 firms rate KROS a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
KROS EPS & revenue forecast
EPS · NEXT QUARTER
$-1.78
Range $-1.97 – $-1.49 · 5 analysts · +107% YoY
Next period, 5 analysts expect Keros Therapeutics Inc to earn $-1.78 a share (range $-1.97 – $-1.49), versus $-0.86 a year earlier. Full-year consensus is $-5.22, growing to $-6.62 the year after.
REVENUE · NEXT QUARTER
$478.6K
Range $0 – $3.0M · 5 analysts · +24% YoY
Revenue is expected to reach $478.6K (range $0 – $3.0M), +24.3% year-over-year. Full-year consensus is $15.6M, rising to $13.7M next year.
Top analysts covering Keros Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on KROS.
#1
Andrew Fein
HC Wainwright & Co. · Rank #55
Buy
$25.00+123.7% to target
Overall win rate
46%
+ Follow
#2
Greg Harrison
Scotiabank · Rank #179
Buy
$26.00+132.7% to target
Overall win rate
38%
+ Follow
#3
Andres Y. Maldonado
HC Wainwright & Co. · Rank #227
Buy
$20.00+79.0% to target
Overall win rate
39%
+ Follow
#4
Andreas Argyrides
Oppenheimer · Rank #242
Buy
$27.00+141.6% to target
Overall win rate
45%
+ Follow
#5
Joseph Catanzaro
Piper Sandler · Rank #272
Buy
$15.00+34.2% to target
Overall win rate
41%
+ Follow
KROS stock forecast FAQ
What is KROS's average 12-month price target?+
The 4 analysts with a live target average $20.60 for Keros Therapeutics Inc over the next 12 months, ranging from a $27.00 high to a $16.00 low.
Is KROS stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 5 analyst ratings, 3 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for KROS?+
The Street-high target is $27.00 (Oppenheimer), and the Street-low is $16.00 (Wedbush). The average of all 4 active targets is $20.60.
How many Wall Street analysts cover KROS?+
5 analysts have an active rating on Keros Therapeutics Inc, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering KROS?+
Among analysts who currently cover KROS, Andrew Fein of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #55). Their current call is Buy with a $25.00 target.
What is Keros Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.78 per share (range $-1.97 – $-1.49) across 5 analysts. Full-year EPS is projected at $-5.22, rising to $-6.62 the following year.
How much revenue is Keros Therapeutics Inc expected to report next quarter?+
Consensus revenue is $478.6K (range $0 – $3.0M). Full-year revenue is projected at $15.6M, growing to $13.7M next year.
Have analysts been upgrading or downgrading KROS lately?+
As of Sep, 3 of 5 firms rate KROS a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their KROS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
